Table 5.
Univariate Cox regression analysis of progression-free survival
| No. | p-value | Hazard ratio (95% CI) | |
|---|---|---|---|
| Age at diagnosis (yr) | |||
| > 35 | 207 | 0.098 | 1 |
| ≤ 35 | 33 | 1.37 (0.94-2.00) | |
| Hormone receptor | |||
| Positive | 175 | 0.069 | 0.70 (0.48-1.03) |
| Negative | 37 | 1 | |
| HER2 | |||
| Positive | 12 | 0.344 | 1.37 (0.72-2.62) |
| Negative | 153 | 1 | |
| Triple-negative phenotype | |||
| No | 137 | 0.038 | 1 |
| Yes | 28 | 1.58 (1.02-2.43) | |
| Pathological subtype | |||
| Ductal | 180 | 0.981 | 1 |
| Other | 35 | 1.00 (0.68-1.45) | |
| Visceral metastases at inclusion | |||
| Yes | 177 | 0.703 | 1.06 (0.79-1.41) |
| No | 69 | 1 | |
| Response to last prior microtubule-inhibiting therapy | |||
| Non-responder | 99 | 0.086 | 1 |
| Responder | 107 | 0.78 (0.58-1.04) |
CI, confidence interval.